Early breast cancer: the 21-gene recurrence score predicts chemo receipt, survival in patients with positive nodes

  • Zhang QH & al.
  • Ann Transl Med
  • 1 Sep 2019

  • curated by Miriam Davis, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The 21-gene recurrence score (RS) is predictive of chemotherapy receipt and survival in patients with early breast cancer (eBCa) with
  • This study, of patients with eBCa with ≥4 positive LN, finds that the 21-gene RS is also predictive of chemotherapy receipt and survival.

Why this matters

  • Findings suggest that patients with ≥4 LN may follow the same chemotherapy guidelines as women with

Study design

  • Retrospective cohort (n=410) of patients with nonmetastatic estrogen receptor-positive BCa with ≥4+ LN (2004-2013).
  • Funding: National Natural Science Foundation of China; others.

Key results

  • The 21-gene RS assay was independently related to chemotherapy receipt, with 59.0%, 68.0%, and 78.0% in the low-, intermediate-, and high-risk RS groups.
  • The 21-gene RS assay was independently related to 5-year BCa-specific survival (BCSS), with 92.7%, 88.3%, and 70.7% in the low-, intermediate-, and high-risk RS group.
  • The 21-gene RS assay was independently related to 5-year OS, with 92.1%, 80.6%, and 66.6% in the low-, intermediate-, and high-risk RS group.
  • Patients with high-risk RS (vs low-risk) had the poorest BCSS (HR, 6.440; P<.001 and os p>
  • Patients with intermediate-risk RS (vs low-risk) had poorer BCSS (HR, 2.832; P=.022) and OS (HR, 3.704; P=.001).

Limitations

  • No controls with